DUBLIN – The EU published a new legal text outlining proposals on regulatory cooperation with the U.S. under the Transatlantic Trade and Investment Partnership (TTIP), a comprehensive free trade agreement currently under negotiation.
DUBLIN – Europe's bright start to the year continued, with two firms taking in more than €77 million (US$88.2 million) in oversubscribed public offerings on the Euronext Exchange Wednesday. Cell therapy developer Bone Therapeutics SA raised €32.2 million in an upsized IPO, while vaccines firm Valneva SE took in more than €45 million in a discounted follow-on offering, to fund its acquisition of the Dukoral oral vaccine against cholera and travelers' diarrhea.
DUBLIN – Quantum Genomics SA is seeking about €9.1 million (US$10 million) in a discounted share issue on the Alternext market in Paris to fund development of a first-in-class hypertension drug called QGC001.
DUBLIN – Swedish start-up Cantargia AB is seeking about SEK44.1 million (US$5.4 million) in an initial public offering (IPO) on the Nasdaq OMX First North exchange, the Nordic region's junior exchange, in order to take forward a new therapeutic concept in cancer.
DUBLIN – Italian gene therapy pioneer Luigi Naldini is one of the co-founders of a new start-up, Genenta Science SpA, a spinout from the San Raffaele Hospital in Milan, which aims to exploit his deep experience in lentiviral vectors in the development of ex vivo engineered autologous cell therapies for cancer.
DUBLIN – Shares in Immupharma plc traded as high as 31 percent Thursday on news that immunomodulatory peptide Lupuzor (IPP-201101) is, after a lengthy delay, finally entering a pivotal phase III trial in systemic lupus erythematosus (SLE).
DUBLIN – The EMA is seeking input from interested parties on the data disclosure aspects of the EU's Clinical Trial Regulation, the overarching piece of legislation that will, from around mid-next year, govern the conduct of clinical trials across the EU.
DUBLIN – As the new year gets up and running, Europe's biotechnology sector is looking to pick up where it left off in 2014, with two firms already filing for initial public offerings (IPOs).
DUBLIN – Roche Holding AG continued its new year shopping spree, putting down an initial €120 million (US$138 million) to acquire Trophos SA, with up to €350 million more to come in milestone payments.
